Exploring the uremic toxins using proteomic technologies

Contributions to Nephrology

Volumn 160, Issue , 2008, Pages 159-171

  Schiffer, E ^a   Mischak, H ^a,b   Vanholder, R ^c  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TOXIN;

HUMAN; KIDNEY DISEASE; METABOLISM; METHODOLOGY; PROTEOMICS; REVIEW; UREMIA;

BIOLOGICAL MARKERS; HUMANS; KIDNEY DISEASES; PROTEOMICS; TOXINS, BIOLOGICAL; UREMIA;

EID: 48949093788     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000125973     Document Type: Review

References (65)

1. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-1823.
2. Vanholder R, Argiles A, Baurmeister U, Brunet P, et al: Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695-725.
3. Vanholder R, De Smet R, Glorieux G, Argiles, et al: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
4. Weissinger EM, Kaiser T, Meert N, De Smet R, et al: Proteomics: a novel tool to unravel the pathophysiology of uraemia. Nephrol Dial Transplant 2004;19:3068-3077.
5. Weissinger EM, Nguyen-Khoa T, Fumeron C, Saltiel C, et al: Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics 2006;6:993-1000.
6. Thongboonkerd V: Proteomics in nephrology: current status and future directions. Am J Nephrol 2004;24:360-378.
7. O'Farrell PH: High-resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-4021.
8. Patterson SD, Aebersold R: Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis 1995;16:1791-1814.
9. Aebersold R, Goodlett DR: Mass spectrometry in proteomics. Chem Rev 2001;101:269-295.
10. Yanagida M: Functional proteomics; current achievements. J Chromatogr B Analyt Technol Biomed Life Sci 2002;771:89-106.
11. Issaq HJ: The role of separation science in proteomics research. Electrophoresis 2001;22:3629-3638.
12. Morrison RS, Kinoshita Y, Johnson MD, Uo T, et al: Proteomic analysis in the neurosciences. Mol Cell Proteomics 2002;1:553-560.
13. Patton WF: Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2002;771:3-31.
14. Thongboonkerd V, Malasit P: Renal and urinary proteomics: current applications and challenges. Proteomics 2005;5:1033-1042.
15. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, et al: Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003;309:18-25.
16. Issaq HJ, Veenstra TD, Conrads TP, Felschow D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292: 587-592.
17. Forde CE, Gonzales AD, Smessaert JM, Murphy GA, et al: A rapid method to capture and screen for transcription factors by SELDI mass spectrometry. Biochem Biophys Res Commun 2002;290:1328-1335.
18. Yip TT, Lomas L: SELDI ProteinChip array in oncoproteomic research. Technol Cancer Res Treat 2002;1:273-280.
19. Merchant M, Weinberger SR: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-1177.
20. Von Eggeling F, Junker K, Fiedle W, Wollscheid V, et al: Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis 2001;22:2898-2902.
21. Issaq HJ, Veenstra TD, Conrads TP, Felschow D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-592.
22. Weinberger SR, Viner RI, Ho P: Tagless extraction-retentate chromatography: a new global protein digestion strategy for monitoring differential protein expression. Electrophoresis 2002;23:3182-3192.
23. Tang N, Tornatore P, Weinberger SR: Current developments in SELDI affinity technology. Mass Spectrom Rev 2004;23:34-44.
24. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, et al: Use of proteomic patter ns in serum to identify ovarian cancer. Lancet 2002;359:572-577.
25. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, et al: Serum proteomics in cancer diagnosis and management. Annu Rev Med 2004;55:97-112.
26. Schaub S, Wilkins J, Weiler T, Sangster K, et al: Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:323-332.
27. Kolch W, Mischak H, Chalmers MJ, Pitt A, Marshall AG: Clinical proteomics: a question of technology. Rapid Commun Mass Spectrom 2004;18:2365.
28. Baggerly KA, Morris JS, Edmonson SR, Coombes KR: Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-309.
29. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments Bioinformatics 2002;20:777-785.
30. Check E: Running before we can walk. Nature 2004;429:496-497.
31. Cheng AJ, Chen LC, Chien KY, Chen YJ, et al: Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005;51;2236-2244.
32. Tolson JP, Flad T, Gnau V, Dihazi H, et al: Differential detection of S100A8 in transitional cell carcinoma of the bladder by pairwise tissue proteomic and immunohistochemical analysis. Proteomics 2006;6:697-708.
33. Aebersold Rl, Mann M: Mass spectrometry-based proteomics. Nature 2003;422:198-207.
34. Wittke S, Kaiser T, Mischak H: Differential polypeptide display: the search for the elusive target. J Chromatogr B Analyt Technol Biomed Life Sci 2004;803:17-26.
35. Issaq HJ, Conrads TP, Janini GM, Veenstra TD: Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis 2002;23:3048-3061.
36. Chen EI, Hewel J, Felding-Habermann B, Yates JR III: Large-scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Mol Cell Proteomics 2006;5:53-56.
37. Cagney G, Park S, Chung C, Tong B, et al: Human tissue prof iling with multidimensional protein identification technology. J Proteome Res 2005;4:1757-1767.
38. Dolnik V, Hutterer KM: Capillary electrophoresis of proteins 1999-2001. Electrophoresis 2001; 22: 4163-4178.
39. Schmitt-Kopplin P, Frommberger M: Capillary electrophoresis-mass spectrometry: 15 years of developments and applications. Electrophoresis 2003;24:3837-3867.
40. Kasicka V: Recent developments in capillary electrophoresis and capillary electrochromatography of peptides. Electrophoresis 2006;27:142-175.
41. Simpson DC, Smith RD: Combining capillary electrophoresis with mass spectrometry for applications in proteomics. Electrophoresis 2005;26:1291-1305.
42. Dolnik V: Capillary electrophoresis of proteins 2003-2005. Electrophoresis 2006;27:126-141.
43. Johannesson N, Wetterhall M, Markides KE, Bergquist J: Monomer surface modifications for rapid peptide analysis by capillary electrophoresis and capillary electrochromatography coupled to electrospray ionization-mass spectrometry. Electrophoresis 2004;25:809-816.
44. Kolch W, Neususs C, Pelzing M, Mischak H: Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005;24:959-977.
45. Hernandez-Borges J, Neususs C, Cifuentes A, Pelzing M: On-line capillary electrophoresis-mass spectrometry for the analysis of biomolecules. Electrophoresis 2004;25:2257-2281.
46. Neususs C, Pelzing M, Macht M: A robust approach for the analysis of peptides in the low femtomole range by capillary electrophoresis-tandem mass spectrometry. Electrophoresis 2002;23:3149-3159.
47. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M: The human urinary proteome contains more than 1,500 proteins including a large proportion of membranes proteins. Genome Biol 2006;7:R80.
48. Rejtar T, Hu P, Juhasz P, Campbell JM, et al: Off-line coupling of high-resolution capillary electrophoresis to MALDI-TOF and TOF/TOF MS. J Proteome Res 2002;1:171-179.
49. Kaiser T, Kamal H, Rank A, Kolb HJ, et al: Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:340-349.
50. Mischak H, Kaiser T, Walden M, Hillmann M, et al: Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004;107:485-495.
51. Theodorescu D, Wittke S, Ross MM, Walden M, et al: Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7:230-240.
52. Chalmers MJ, Mackay CL, Hendrickson CL, Wittke S, et al: Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem 2005; 77:7163-7171.
53. Zurbig P, Renfrow MB, Schiffer E, Novak J, et al: Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006;27:2111-2125.
54. Schepky AG, Bensch KW, Schulz-Knappe P, Forssmann WG: Human hemofiltrate as a source of circulating bioactive peptides: determination of amino acids, peptides and proteins. Biomed Chromatogr 1994;8:90-94.
55. Brunner H, Mann H, Essers U, Schultheis R, et al: Preparative isolation of middle molecular weight fractions from the hemofiltrate of patients with chronic uremia. Artif Organs 1978;2:375-377.
56. Schulz-Knappe P, Schrader M, Standker L, Richter R, et al: Peptide bank generated by large-scale preparation of circulating human peptides. J Chromatogr A 1997;776;125-132.
57. Schrader M, Jurgens M, Hess R, Schulz-Knappe P, et al: Matrix-assisted laser desorption/ionisation mass spectrometry guided purification of human guanylin from blood ultrafiltrate. J Chromatogr A 1997;776:139-145.
58. John H, Radtke K, Standker L, Forssmann WG: Identification and characterization of novel endogenous proteolytic forms of the human angiogenesis inhibitors restin and endostatin. Biochim Biophys Acta 2005;1747:161-170.
59. Fricke K, Schulz A, John H, Forssmann WG, Maronde E: Isolation and characterization of a novel proopiomelanocortin-derived peptide from hemofiltrate of chronic renal failure patients. Endocrinology 2005;146:2060-2068.
60. Wagner K, Miliotis T, Marko-Varga G, Bischoff R, Unger KK: An automated on-line multidimensional HPLC system for protein and peptide mapping with integrated sample preparation. Anal Chem 2002;74:809-820.
61. Ward RA, Brinkley KA: A proteomic analysis of proteins removed by ultrafiltration during extracorporeal renal replacement therapy; in Thongboonkerd V, Klein JB (eds): Proteomics in Nephrology. Contrib Nephrol. Basel, Karger, 2004, vol 141, pp 280-291.
62. 2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701-706.
63. Lefler DM, Pafford RG, Black NA, Raymond JR, Arthur JM: Identification of proteins in slow continuous ultrafiltrate by reversed-phase chromatography and proteomics. J Proteome Res 2004; 3:1254-1260.
64. Molina H, Bunkenborg J, Reddy GH, Muthusamy B, Scheel PJ, Pandey A: A proteomic analysis of human hemodialysis fluid. Mol Cell Proteomics Mol Cell Proteomics 2005;4:637-650.
65. Kaiser T, Hermann A, Kielstein JT, Wittke S, et al: Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. J Chromatogr A 2003;1013:157-171.